Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hemachudha, T.
Right arrow Articles by Giffels, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hemachudha, T.
Right arrow Articles by Giffels, J. J.
NEUROLOGY 1988;38:42
© 1988 American Academy of Neurology

Immunologic studies of patients with chronic encephalitis induced by post-exposure Semple rabies vaccine

Thiravat Hemachudha, MD, Diane E. Griffin, MD, PhD, Richard T. Johnson, MD and J. Joseph Giffels, BA

Neurology Division, Department of Medicine (Dr. Hemachudha), Chulalongkorn University Hospital, Bangkok, Thailand; and the Department of Neurology (Drs. Hemachudha, Griffin, and Johnson, and Mr. Giffels), The Johns Hopkins University School of Medicine, Baltimore, MD.

Neurologic complications of brain tissue-derived rabies vaccine may be chronic or progressive. Lymphocytes and serum from three patients with this form of encephalitis were studied. Two patients had positive lymphoproliferation to purified myelin, two had antibody to white matter, and one had antibody to myelin basic protein. No patient had antibody to proteolipid protein, myelin-associated glycoprotein, or cerebroside.

Address correspondence and reprint requests to Dr. Griffin, Department of Neurology, Meyer 6-181, The Johns Hopkins Medical Institutions, Baltimore, MD 21205.

Supported by grants from the National Multiple Sclerosis Society and Chulalongkorn University, and a Fogarty Fellowship to Dr. Hemachudha.

Received December 22, 1986. Accepted for publication in final form March 18, 1987.




This article has been cited by other articles:


Home page
 NeurologyHome page
S. Tenembaum, T. Chitnis, J. Ness, J. S. Hahn, and for the International Pediatric MS Study Group
Acute disseminated encephalomyelitis
Neurology, April 17, 2007; 68(16_suppl_2): S23 - S36.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Sharma, C. B. Davis, L. A. P. Tobia, D. C. Kwok, M. G. Tucci, E. R. Gore, D. J. Herzyk, and T. K. Hart
Comparative Pharmacodynamics of Keliximab and Clenoliximab in Transgenic Mice Bearing Human CD4
J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 33 - 41.
[Abstract] [Full Text]

Home page
 Mult SclerHome page
A J Coles, M G Wing, and D A. Compston
Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy
Multiple Sclerosis, June 1, 1998; 4(3): 232 - 238.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by AAN Enterprises, Inc.